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Abstract
Introduction: Mutations in the BRCA1 and BRCA2 genes are responsible for only a part of hereditary breast cancer
(HBC). The origins of “non-BRCA“ HBC in families may be attributed in part to rare mutations in genes conferring
moderate risk, such as CHEK2, which encodes for an upstream regulator of BRCA1. Previous studies have
demonstrated an association between CHEK2 founder mutations and non-BRCA HBC. However, very few data on
the entire coding sequence of this gene are available.
Methods: We investigated the contribution of CHEK2 mutations to non-BRCA HBC by direct sequencing of its
whole coding sequence in 507 non-BRCA HBC cases and 513 controls.
Results: We observed 16 mutations in cases and 4 in controls, including 9 missense variants of uncertain
consequence. Using both in silico tools and an in vitro kinase activity test, the majority of the variants were found
likely to be deleterious for protein function. One variant present in both cases and controls was proposed to be
neutral. Removing this variant from the pool of potentially deleterious variants gave a mutation frequency of 1.48%
for cases and 0.29% for controls (P = 0.0040). The odds ratio of breast cancer in the presence of a deleterious
CHEK2 mutation was 5.18.
Conclusions: Our work indicates that a variety of deleterious CHEK2 alleles make an appreciable contribution to
breast cancer susceptibility, and their identification could help in the clinical management of patients carrying a
CHEK2 mutation.
Introduction
Breast cancer is one of the main causes of cancer-
related deaths among women worldwide, with 5% to
10% of cases being due to hereditary risk. However,
mutations in the two major genes, BRCA1 and BRCA2,
are found in only 15% to 20% of hereditary breast can-
cer (HBC) families [1]. Several studies have reported evi-
d e n c et h a tg e r m l i n em u t a t i o ns in other susceptibility
genes, such as ATM, PABL2, BRIP1 and CHEK2,m i g h t
be the predisposing factor in some HBC families [2-5].
In addition, the lower penetrance of these mutations
suggests that they might act in concert with other her-
editary factors [6-10].
CHEK2 is the human homolog of Rad53 (Saccharo-
myces cerevisiae)a n dCds1 (Schizosaccharomyces
pombe). This family of kinases is characterized by
several domains: a SQ/TQ cluster domain, a Forkhead-
associated (FHA) domain and a Ser/Thr kinase domain
[11]. In response to DNA double-strand breaks or repli-
cative stress, CHEK2 is activated by the kinases ATM
and ATR [12]. These proteins catalyze the phosphoryla-
tion of threonine 68 of CHEK2, causing its transient
dimerization via the FHA domain. This leads to CHEK2
trans-autophosphorylation and its full activation [13].
Activated CHEK2 monomers phosphorylate, in turn,
numerous downstream substrates, including the P53
tumor suppressor, CDC25 family proteins and serine
988 of BRCA1, activating cell-cycle checkpoints and
increasing DNA repair efficiency [14-17]. These interac-
tions suggest that CHEK2 may also play a role in breast
cancer [14].
Germline CHEK2 mutations are associated with breast
cancer in different populations. For example, heterozyg-
osity for the well-studied c.1100delC mutation, present
in 1.4% of the Finnish population and in 0.2% of the
Polish population, confers a relative risk for developing
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[18,19] Likewise, the variant Ile157Thr, present in 5.3%
of the Finnish population and in 4.8% of the Polish
population, confers a relative risk of breast cancer of 1.5
[20,21].
However, very few groups have studied the entire
CHEK2 gene in HBC [22-25]. It is essential to establish
a causal link between sequence variants and CHEK2
function. Little is known about the impact of missense
mutations on protein function, although substitutions in
the FHA domain and the kinase domain have been
shown to abolish activity [22,26,27]. In this study, we
screened the whole CHEK2 coding sequence for muta-
tions in non-BRCA HBC families and a control popula-
tion without any family history of breast cancer. Point
mutations were evaluated by in silico analyses and an in
vitro kinase activity test.
Materials and methods
Subjects
We recruited 507 cases with HBC risk through the
oncogenetic consultation department at the Centre Jean
Perrin (Clermont-Ferrand, France). This group consisted
of 258 families with 3 breast cancers in the same famil-
ial branch with at least 2 cases related in the first
degree, 237 families with 2 cases of breast cancer in the
same branch with at least 1 breast cancer diagnosed
before age 40 years or with bilateral breast cancer, and
12 families with 2 cases of breast cancer and at least 1
male breast cancer. One affected patient per HBC family
was screened for variants in CHEK2.C a s e sw i t hH B C
linked to BRCA1 or BRCA2 mutations were excluded by
direct sequencing of both genes and by multiplex liga-
tion-dependent probe amplification of BRCA1. A control
group recruited from the same region of France con-
sisted of 513 female volunteers in good health and with-
out any personal or family history of breast or
gynecologic cancers at the time of the recruitment. All
subjects signed informed consent agreements that were
approved by the CCPPRB Regional Ethics Committee
(Auvergne, France). To assess the relationship between
CHEK2 variants and breast cancer risk, logistic regres-
sion was used to obtain odds ratios (as estimates of rela-
tive risk) and 95% confidence intervals [28].
DNA extraction and sequencing
To identify variants in the CHEK2 gene, exons 2 to 14
were analyzed (exon 1 is noncoding, and exon 15, repre-
senting 89 bp of coding sequence, could not be analyzed
for all the patients, owing to the presence of repeated
sequences) in both patients and controls for the geno-
mic sequence [GenBank:NG_008150.1] and for the
cDNA sequence [GenBank:NM_007194.3] [29] DNA
was extracted from 10 ml of peripheral blood collected
on heparin/lithium using a Genomix blood DNA extrac-
tion kit according to the manufacturer’s instructions
(Talent srl, Trieste, Italy). Samples were resuspended
with Tris-ethylenediaminetetraacetic acid (EDTA) (TE)
( 1 0m MT r i s ,1m ME D T A ,p H8 . 0 ) .E x o n s2t o1 0 ,
including intron-exon boundaries, were amplified by
using standard PCR techniques (conditions and primers
available on request). Because of the multiple copies of
CHEK2 pseudogenes, we used a nested PCR strategy,
d e s c r i b e dp r e v i o u s l yb yS o d h aet al. [10], to specifically
amplify exons 10 to 14 [30]. Sequence reactions were
performed on PCR products purified by ExoSAP-IT
(Affymetrix, Inc, Santa Clara, CA, USA) using BigDye v3
reagents (Applied Biosystems/Life Technologies, Foster
City, CA, USA) (primers available on request), purified
in Sephadex G-50 fine (G5080; Sigma-Aldrich, St Louis,
MO, USA) and analyzed using a 3130xl capillary elec-
trophoresis system (Applied Biosystems/Life Technolo-
gies). Alignment to the reference sequences was
performed using SeqMan NGen software (DNASTAR,
Inc, Madison, WI, USA).
Bioinformatics studies
For each missense variant, prediction of the impact of
the mutation on the protein was assessed by calculating
the SIFT (Sorting Intolerant From Tolerant), Align-
GVGD and PolyPhen-2 (Polymorphism Phenotyping v2)
software tool scores [31-34]. Align-GVGD predictions
and SIFT score were computed using the ortholog align-
ment of exons 2 to 14 of CHEK2 derived by using Ala-
mut software (Interactive Biosoftware, Rouen, France)
[32]. Included were human (Homo sapiens)[ G e n B a n k :
NP_009125.1], chimpanzee (Pan troglodytes) [GenBank:
XP_001172759.1], macaque (Macaca)[ G e n B a n k :
XP_001101658.1], rat (Rattus norvegicus)[ G e n B a n k :
NP_446129.1], mouse (Mus musculus)[ G e n B a n k :
NP_057890.1], dog (Canis lupus familiaris)[ G e n B a n k :
XP_543464.2], cow (Bos taurus)[ G e n B a n k :
NP_001029703.1], chicken (Gallus gallus)[ G e n B a n k :
XP_001232074.1], frog (Xenopus tropicalis)[ G e n B a n k :
NP_001119996.1] and pufferfish (Tetraodon nigroviridis)
[UniProtKB/TrEMBL:Q4TI84], all extracted from the
Ensembl Compara database [35]. PolyPhen-2 score was
calculated online using default settings and accession
numbers [UniProtKB/Swiss-Prot:O96017] [36,37]. The
potential impact on splicing was studied using SpliceSi-
teFinder, MaxEntScan and GeneSplicer prediction soft-
ware [38-40].
Plasmid constructs
The pDream2.1 cloning vector (GenScript USA Inc, Pis-
cataway, NJ, USA) carrying the full-length human
CHEK2 coding sequence tagged with an N-terminal
FLAG extension under the control of the LacZ
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contain the wild-type (WT) sequence. The Stratagene
QuickChange II Site-Directed Mutagenesis Kit (Agilent
Technologies, Inc, Santa Clara, CA, USA) was used to
generate mutant constructs Ser39Phe, Pro85Arg,
Arg117Gly, Arg145Trp, Glu161Del, Arg180His, Lys224-
Glu, Lys244Arg, Met367fsX15, Tyr390Ser and
Thr476Met, with the corresponding primers (available
on request) in accordance with the manufacturer’s
recommendations. All constructs were confirmed by
sequencing of the entire coding region of the gene (pri-
mers available on request).
Expression and extraction of recombinant CHEK2 protein
Escherichia coli strain BL21 was transformed with
pDream plasmids(GenScript USA Inc) encoding WT or
mutated Flag-CHEK2. Cultures were grown at 37°C in
Luria Broth media containing 100 μg/ml ampicillin until
absorbance at 600 nm reached 0.6 before isopropyl b-D-
1-thiogalactopyranoside was added to a final concentra-
tion of 0.5 mM and incubated for 3 hours. Extraction of
total bacterial proteins was performed as described pre-
viously [26].
Kinase activity of CHEK2 recombinant proteins
Omnia kinase assay buffer (18 μl; Invitrogen/Life Tech-
nologies, Carlsbad, CA, USA) containing 10 μM Sox sub-
strate peptide, 1 mM ATP, 0.2 mM dithiothreitol and 2
μl of 10 × Omnia buffer was incubated for 5 minutes at
room temperature and aliquoted to a 96-well plate to
ensure equal amounts of the chemosensor. For each
assay reaction, 1.5 μg of total bacterial protein from
induced cultures containing WT or mutated Flag-
CHEK2 or from untransformed E. coli, were then added
and mixed gently. CHEK2 protein was added at the
moment of the fluorescence acquisition, allowing us to
follow the kinetics of substrate phosphorylation. CHEK2
kinase activity was monitored with excitation at 360 nm
and emission at 485 nm. Fluorescence was detected using
an Infinite 200 PRO plate reader (Tecan Group Ltd,
Männedorf, Switzerland) for 60 minutes at room tem-
perature. For each mutation,a na v e r a g eo fs i xw e l l sa n d
three independent experiments were conducted. Each
curve was normalized by linear regression using the slope
of the corresponding nontransformed bacterial protein
extract curve. Thus the slope of the resulting curves
represents the ability of CHEK2 recombinant protein to
phosphorylate the substrate (see Additional file 1).
Results
CHEK2 mutations contribute to hereditary breast cancer
To evaluate the contribution of CHEK2 mutations to
HBC, we sequenced the coding sequence of the gene,
including intron-exon boundaries. We observed 13
different variants in 16 of 507 cases and 4 different var-
iants in 4 of 513 controls (Table 1). In the case popula-
tion, there were eight different novel missense
mutations and one previously described in osteosarco-
mas [41], as well as one nonsense mutation, one novel
frame shift mutation, one splice donor mutation and
three patients (0.59%) with the c.1100delC
(Met367fsX13) mutation (Figure 1). No mutation hot-
spots were observed (Figure 1). Mutations among con-
trols included three missense mutations and one
affecting a splice donor site. To the best of our knowl-
edge, we are the first to report all mutations found in
the control population. The missense mutation
Lys244Arg was found in both cases and controls. The
mutation frequency was higher for the cases (16 of
1,014 vs 4 of 1,026; P = 0.0065) (Table 2). The OR of
CHEK2 mutation carriers was 4.15 (95% CI = 1.38 to
12.50), suggesting that CHEK2 contributes to hereditary
risk of breast cancer.
Bioinformatics study
Canonical splice donor and acceptor sites were evalu-
ated using SpliceSiteFinder, MaxEntScan and GeneSpli-
cer. All three programs provided consistent information
that the two mutations affecting splice donor sites abro-
gate splicing of the exons concerned (Table 1). We thus
considered these mutations to be deleterious. Because
the effect of an amino substitution can be difficult to
assess, a combination of three different in silico analyses
(Align-GVGD class, SIFT prediction and PolyPhen-2
prediction) was used. For each missense variation, we
compiled these three scores to propose a diagnosis. Mis-
sense variants were considered probably deleterious if at
least one deleterious score was obtained and probably
benign if three benign scores were obtained. Class above
C35 was considered the threshold for deleterious var-
iants in Align-GVGD.
Substitutions with a SIFT score less than 0.05 are pre-
dicted to be deleterious. A SIFT median sequence con-
servation score cutoff of 3.25 was used to measure the
diversity of the sequences used for prediction, and a
score greater than 3.25 could indicate that the predic-
tion was based on closely related sequences. This would
result in a low confidence score if the variant were con-
sidered deleterious. No SIFT median sequence conserva-
tion score reached this cutoff, indicating that the aligned
sequences were diverse enough for confident prediction
of substitutions that should affect protein function. One
mutation, Lys244Arg, present in both cases and con-
trols, was not considered to be potentially deleterious
on the basis of the results of any of the algorithms used,
suggesting it is a rare but benign variant. All other mis-
sense variants were considered potentially damaging on
the basis of at least one measure.
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To evaluate whether missense variants inhibit the func-
tion of the CHEK2 protein, an in vitro kinase activity
test based on a CHEK2-specific substrate peptide carry-
ing a C-terminal SOX was developed [42].
Overexpression of recombinant CHEK2 at high levels in
bacteria is associated with CHEK2 autophosphorylation
and activation in the absence of DNA damage [13]. This
property was used to obtain recombinant activated
CHEK2. Upon the phosphorylation of the SOX-specific
Table 1 CHEK2 mutations identified in French women with hereditary breast cancer and a control group of unaffected
women
Mutation Amino acid
change
Exon Protein
domain
Splicing
effect
Align-
GVGD
class
SIFT median sequence
conservation score
SIFT
prediction
PolyPhen-2
prediction
Proposed
diagnosis
Case
population (n
= 13)
190G > A [49]
(two cases)
Glu64Lys 2 SQ/TQ - C15 2.23 Tolerated Benign Probably
benign
190G > T Glu64X 2 SQ/TQ - - - - Probably
deleterious
254C > G
[23,41]
Pro85Arg 2 - - C0 2.15 Tolerated Probably
damaging
Probably
deleterious
349A > G [23] Arg117Gly 3 FHA - C65 2.07 Deleterious Probably
damaging
Probably
deleterious
670A > G Lys224Glu 5 Kinase - C0 2.05 Tolerated Benign Probably
benign
731A > G Lys244Arg 6 Kinase - C0 2.04 Tolerated Benign Probably
benign
751A > T [23] Ile251Phe 6 Kinase - C0 2.04 Tolerated Probably
damaging
Probably
deleterious
846+4_846
+7del
- 7 - Possibly
skip exon 7
- - - - Probably
deleterious
1100del (three
cases)
Thr367MetfsX15 11 Kinase - - - - - Probably
deleterious
1169A > C Tyr390Ser 11 Kinase - C0 2.04 Deleterious Probably
damaging
Probably
deleterious
1281C > A Phe427Leu 12 Kinase - C0 2.04 Deleterious Probably
damaging
Probably
deleterious
1427C > T [23] Thr476Met 13 Kinase - C0 2.05 Deleterious Probably
damaging
Probably
deleterious
Control
population (n
=4 )
116C > T Ser39Phe 2 SQ/TQ - C65 3.10 Deleterious Benign Probably
deleterious
251A > G Glu84Gly 2 - - C65 2.17 Tolerated Probably
damaging
Probably
deleterious
731A > G Lys244Arg 6 Kinase - C0 2.04 Tolerated Benign Probably
benign
792+1dup - 6 - Probably
skip exon 6
- - - - Probably
deleterious
Additional mutations tested for kinase function [27]
410G > A Arg137Gln 3 FHA - C0 2.22 Tolerated Benign Probably
benign
433C > T Arg145Trp 3 FHA - C65 2.05 Tolerated Probably
damaging
Probably
deleterious
481_483del Glu161del 4 FHA - - - - - Probably
deleterious
539G > A Arg180His 4 FHA - C0 2.04 Tolerated Probably
damaging
Probably
deleterious
Align-GVGD, SIFT (Sorting Intolerant From Tolerant) and PolyPhen-2 (Polymorphism Phenotyping v2) software tool scores and splicing effect were calculated. The
possible impact of the different mutations on CHEK2 function is proposed. FHA = Forkhead-associated domain.
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SOX results in an increase in fluorescence at 485 nm.
Activity was detected for the WT protein but not for
proteins extracted from nontransformed bacteria or
recombinant CHEK2 protein carrying c.1100delC (Fig-
u r e2 ) .O n l ym i s s e n s ev a r i a n t sw e r et e s t e df o rk i n a s e
activity. c.190G > T (Glu64X), c.825_826del, c.846+4_
+7del and c.792+1dup were considered deleterious
Figure 1 Position of CHEK2 mutations found in French non-BRCA HBC and control populations. FHA = Forkhead-associated domain; SQ/
TQ = SQ/TQ cluster domain.
Table 2 CHEK2 mutations were more frequent in cases than in controls
CHEK2 mutation type Controls
(n = 1,026)
a
Allelic frequency in
controls
Cases
(n = 1,014)
a
Allelic frequency in cases P value OR 95% CI
Any CHEK2 mutation 4 0.39% 16 1.58% 0.0065 4.15 (1.38 to 12.50)
CHEK2 deleterious
mutations
3 0.29% 15 1.48% 0.0042 5.18 (1.49 to 18.00)
an indicates the number of alleles.
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kinase activity in vitro by Sodha et al. [27] were
included to validate the assay.
Three different classes of kinase activity were
observed: WT-like, intermediate and null (Figure 2).
Mutations Ser39Phe, Arg145Trp and Arg137Gln exhib-
ited WT-like kinase activity, suggesting that these muta-
tions do not affect the ability of recombinant CHEK2 to
recognize, bind and phosphorylate its substrate (Figure
2). The mutants Pro85Arg, Arg180His and Lys244Arg
had significantly lower, but not null, kinase activity (Fig-
ure 2), which placed them in the intermediate class. The
mutations Glu161Del, Lys224Glu, Thr476Met and
Tyr380Ser did not have any kinase activity. Nine of the
eleven mutations showed kinase activity consistent with
the in silico analysis, demonstrating the good but
incomplete correlation of those two approaches (Table
3).
Figure 2 Kinase activity of recombinant Flag-CHEK2 protein.T o t a lp r o t e i ne x t r a c t( 1 . 5μg) was tested for the ability to phosphorylate a
fluorescent substrate. The slope of the resulting curve represents Flag-CHEK2 kinase activity. The slope of the wild-type (WT) Flag-CHEK2 kinase
activity curve was normalized to 1. Nontransformed protein extracts (NT) and mutant c.1100delC served as controls. Each point represents an
average of five measurements performed in triplicate.
Table 3 Relationship between in silico and in vitro results
Mutation Domain In silico conclusion In vitro conclusion Concordance
Ser39Phe SQ/TQ Probably deleterious WT-like No
Pro85Arg Unknown function Probably deleterious Intermediate Yes
Arg137Gln FHA Probably benign WT-like Yes
Arg145Trp FHA Probably deleterious Intermediate Yes
Glu161Del FHA Probably deleterious Null Yes
Arg180His FHA Probably deleterious Intermediate Yes
Lys 224Glu Kinase core Probably benign Null No
Lys244Arg Kinase core Probably benign WT-like Yes
Met367fsX13 Kinase core Probably deleterious Null Yes
Tyr390Ser Kinase core Probably deleterious Null Yes
Thr476Met Kinase core Probably deleterious Null Yes
Desrichard et al. Breast Cancer Research 2011, 13:R119
http://breast-cancer-research.com/content/13/6/R119
Page 6 of 11Both in silico and in vitro analyses suggested that the
variant Lys244Arg, present in cases and controls, can be
considered benign. This variant was thus removed from
the pool of potentially deleterious CHEK2 variants that
contribute to HBC. As a result, the mutation frequency
was reduced to 1.48% for cases and 0.29% for controls
(Table 2). This difference remained significant (P =
0.0042), and the OR associated with the presence of a
deleterious mutation was increased to 5.18 (95% CI:
1.49 to 18.00).
Discussion
We found strong evidence of an association between
CHEK2 variants and HBC, with an OR of 5.18. Of 16
different mutations, 9 were unreferenced variants. This
demonstrates that, in populations without founder
mutations, an aggregate of rare variants makes CHEK2
an appreciable breast cancer risk gene.
The functional consequences of missense variants can
be difficult to establish, and in estimating associated
risks it is important to separate deleterious from neutral
variants. We were unfortunately unable to complement
the functional data presented here with a study of the
cosegregation of these variants with cancer, because
only the index case was available for analysis in the
majority of families.
Missense variant Ser39Phe was predicted as probably
deleterious by two of the three scores (SIFT and Align-
GVGD), but exhibited WT-like kinase activity. This dis-
cordance may suggest that not all deleterious changes in
the CHEK2 protein can be revealed by the in vitro
kinase activity test, most notably for changes outside the
catalytic domain. Changes affecting interactions with
upstream activators such as ATM, for example, may not
be detectable by our measure. In contrast, Lys224Glu
was predicted to be a tolerable change by the three
scores, but exhibited null kinase activity, demonstrating
the complementarity of those two approaches.
Further functional tests, such as expression in eukar-
yotic cells, followed by measures of activation by DNA
strand breaks, protein stability and interaction with cel-
lular partners may be necessary to appreciate all effects
of these mutations, especially for those where the in
silico and in vitro conclusions differ. We thus retain this
variant as potentially deleterious, unlike Lys244Arg,
which was characterized as benign by all measures.
The association between the CHEK2 gene and breast
cancer risk has been supported mainly by case-control
studies of founder mutations such as 1100delC, I157T
(frequent in northern and eastern Europe) or the Polish
founder mutation IVS2+1 G > A (c.444+1G > A)
[19,20,24,43,44]. In our population, only one of these
founder mutations was observed, accounting for one-
third of deleterious mutations. Analysis of the entire
coding sequence was necessary to capture the majority
of the different mutations present. This might be the
case for other populations where the frequency of the
CHEK2 founder mutations is low.
In Table 4, to give an overview of CHEK2 contribution
to breast cancer, we summarize the results of 36 different
case-control studies from different countries where the
presence of variants was assessed by allele-specific
sequencing or DNA sequencing of the entire gene. The
ORs of breast cancer from the different studies of
c.1100delC are similar, regardless of the selection of
cases, with a combined OR of 2.77. We also found com-
parable results for the other protein-truncating mutation
c.444+1G > A, which is less frequent but has an OR simi-
lar to that for c.1100delC. No positive association with
HBC was observed, possible due to the very low fre-
quency of the variant in both cases and controls. The fre-
quent variant I157T was associated with lower ORs than
null mutations. Although this variant has been associated
with breast cancer risk in early-onset or unselected cases,
in our study it did not exhibit a significant association
with HBC. Although the frequency of these deleterious
mutations was different among populations, the ORs
associated with breast cancer were consistent for the two
null mutations and lower for the missense mutation.
These data were collected using allele-specific sequen-
cing, suggesting that testing for CHEK2 founder muta-
tions is cost-effective in some populations because the
variants are sufficiently common and the test is relatively
inexpensive. Consequently, however, these techniques
exclude mutations present elsewhere in the gene.
Because the c.1100delC allele does not seem to be
present in southern Europeans or in most non-Cauca-
sian populations [45-47], other research groups have
used full-gene sequencing to determine whether other
variants contribute to breast cancer risk. There is a posi-
tive association between CHEK2 variants and HBC in
the Australian, Canadian, North American, German and
now French, but not Czech Republic, populations
[22-25]. This suggests that CHEK2 analysis in popula-
tions where the common founder mutations are rare
requires screening of the entire sequence.
Narod’s [48] recent review supports the view that test-
ing non-BRCA HBC families for mutations in CHEK2
can provide useful information to evaluate the risk of
breast cancer and suggests that the relatively high cost
of sequencing makes only the targeted search of fre-
quent mutations cost-effective. In certain populations,
one or a few mutations do indeed capture the majority
of CHEK2 variants associated with cancer risk. In most
regions, however, this allele-specific approach is inade-
quate and a full-resequencing strategy should be consid-
ered. The rapidly falling cost of resequencing, as well as
alternate techniques, should make this possible.
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The usefulness of the information gained from genetic
analysis of CHEK2 is currently a matter of debate. As
we have discussed, the risk of breast cancer for a
woman with a null mutation in this gene is increased
two- to fivefold. Increased breast surveillance may be
proposed for carriers, but when counseling a family with
many breast cancer cases, only some of whom carry the
CHEK2 mutation, it is unclear what advice may be given
to noncarriers. Collecting research information on
CHEK2 mutations, however, serves to advance our
understanding of the contribution of this gene to heredi-
tary cancer risk.
Web resources
The URLs for the accession numbers and data presented
herein are as follows:
Entrez gene database: http://www.ncbi.nlm.nih.gov/
gene (for CHEK2 sequencing)
Ensembl Compara database: http://www.ensembl.org/
info/docs/compara/index.html
Table 4 Odds ratio for breast cancer among women with CHEK2 variants
Variants References Geographic populations Case
populations
Mutation frequency
in controls (n/total)
Mutation frequency
in cases (n/total)
OR (95%
(CI)
c.1100delC Mixed populations All studies 0.33% (559/166,596) 0.90% (861/94,076) 2.77 (2.49
to 3.08)**
[19,22,25,45,47,50-59] AJ, AUS, B, CDN, CZ, DK, E, FIN,
G, IRL, KP, NL, S, UK, USA
UBC 0.31% (2,502/80,168) 0.80% (464/58,290) 2.56 (2.19
to 2.99)**
[3,19,22,24,25,50,54,60-64] B, CDN, CZ, D, FIN, NL, S, UK,
USA
HBC 0.39% (111/28,402) 1.27% (215/17,000) 3.29 (2.61
to 4.14)**
[23,54,65] D, USA, AUS, CDN EOBC 0.14% (14/9,846) 0.46% (21/4,588) 2.77 (1.23
to 6.26)**
[18,53,60,66,67] AJ, DK, G, FIN, NL, RUS, UK, USA BBC 0.43% (130/29,936) 1.35% (142/10,496) 3.17 (2.49
to 4.03)**
c.444+1G >
A
(IVS2+1G >
A)
Mixed populations All studies 0.19% (82/42,266) 0.66% (217/33,142) 3.45 (2.67
to 4.46)**
[68,69] PL EOBC 0.19% (49/25,426) 0.59% (91/15,338) 3.10 (2.19
to 4.39)**
[24,43] D, BY HBC 0.12% (3/2,586) 0.26% (4/1,536) 2.25 (0.5 to
10.08) (NS)
[43,59,70] D, BY, PL UBC 0.20% (28/14,254) 0.61% (113/18,604) 3.12 (2.06
to 4.72)**
I157T Mixed populations All studies 2.14% (1,031/48,268) 3.11% (1062/34,128) 1.56 (1.43
to 1.70)**
[22,23,65,68] PL, USA, AUS, CDN EOBC 1.46% (270/18,432) 1.99% (215/10,780) 1.59 (1.32
to 1.91)**
[20,22,24,43,71] D, BY, FIN, NL, USA HBC 1.77% (116/6,544) 1.51% (47/3,118) 0.89 (0.60
to 1.20)
(NS)
[20,22,25,43,44,59,70] By, CZ, D, FIN, PL, USA UBC 2.04% (644/31,600) 2.95% (807/27,346) 1.48 (1.33
to 1.65)**
Whole-
gene
studies
[22] USA UBC 0.57% (24/4,210) 0.50% (4/800) 0.88 (0.3 to
2.55) (NS)
[24] D HBC 0.50% (18/3,630) 3.00% (31/1,032) 6.38 (3.54
to 11.5)**
[25] CZ HBC 1.39% (19/1,366) 2.01% (27/1,346) 1.46 (0.80
to 2.65)
(NS)
F HBC 0.39% (4/1,026) 1.58% (16/1,014) 4.15 (1.38
to 12.50)**
[23] USA, CDN, AUS EOBC 1.84% (40/2,178) 4.91% (6/2,484) 2.76 (1.65
to 4.60)**
BBC = bilateral breast cancer; EOBC = early-onset breast cancer; HBC = hereditary breast cancer not related to a BRCA mutation; UBC = unselected breast cancer;
AJ = Ashkenazi Jewish; AUS = Australia; B = Belgium; BY = Belarus; CDN = Canada; CZ = Czech Republic; D = Germany; DK = Denmark; E = Spain; F = France; FIN
= Finland; IRL = Ireland; KP = South Korea; NL = The Netherlands; PL = Poland; RUS = Russia; S = Sweden; UK = United Kingdom; USA = United States of
America; NS = nonsignificant (P < 0.05); **P < 0.0001. Participant numbers may vary from original publications because of exclusion of study subgroups.
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Additional material
Additional file 1: Supplementary data: control kinase activity of
recombinant CHEK2 protein. Total protein extract (1.5 μg) was added
to the substrate peptide. Fluorescence was measured at 485 nm for 1
hour. Wild type (WT), nontransformed protein extracts (NT) and mutant
c.1100delC served as controls, and kinase activity of bacterially expressed
mutants are sorted by domain. Each point on the curve represents an
average of six measurements repeated in triplicate.
Abbreviations
HBC: hereditary breast cancer; FHA: Forkhead-associated; WT: wild type.
Acknowledgements
We thank Molecular Genetic Diagnosis team and Dr Bernard-Gallon’s team
for technical assistance. The Ligue Contre le Cancer d’Auvergne provided
financial support. A. Desrichard was funded by grants from the Conseil
Regional d’Auvergne and FEDER.
Author details
1Laboratoire Diagnostic Génétique et Moléculaire, Centre Jean Perrin, 58 rue
Montalembert, F-63011 Clermont-Ferrand, France.
2Clermont Université,
Université d’Auvergne, 28 place Henri Dunant, EA 4233, BP 10448, F-63001
Clermont Ferrand, France.
Authors’ contributions
AD contributed to the sequencing of CHEK2, designed and performed the
kinase activity, participated in the in silico analyses and drafted the
manuscript. YB provided expert technical advice, and helped to draft the
manuscript. NU designed the study, participated in the sequencing of CHEK2
and provided expertise for the in silico analyses. YJB supervised the study
and helped to draft the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 March 2011 Revised: 10 November 2011
Accepted: 24 November 2011 Published: 24 November 2011
References
1. Panda S, Isbatan A, Adami GR: Modification of the ATM/ATR directed DNA
damage response state with aging and long after hepatocyte
senescence induction in vivo. Mech Ageing Dev 2008, 129:332-340.
2. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S,
Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S,
Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK),
Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting
protein, is a breast cancer susceptibility gene. Nat Genet 2007,
39:165-167.
3. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A,
Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M,
Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L,
Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-
Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S,
Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D,
Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, CHEK2-Breast
Cancer Consortium: Low-penetrance susceptibility to breast cancer due
to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat
Genet 2002, 31:55-59.
4. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B,
Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Breast
Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N:
ATM mutations that cause ataxia-telangiectasia are breast cancer
susceptibility alleles. Nat Genet 2006, 38:873-875.
5. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T,
Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG,
Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF,
Stratton MR, Rahman N: Truncating mutations in the Fanconi anemia J
gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat
Genet 2006, 38:1239-1241.
6. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D:
Evidence for further breast cancer susceptibility genes in addition to
BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001,
21:1-18.
7. Ponder BA: Cancer genetics. Nature 2001, 411:336-341.
8. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J,
Ponder BJ, Easton DF: A comprehensive model for familial breast cancer
incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002, 86:76-83.
9. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA:
Polygenic susceptibility to breast cancer and implications for prevention.
Nat Genet 2002, 31:33-36.
10. Sodha N, Houlston RS, Bullock S, Yuille MA, Chu C, Turner G, Eeles RA:
Increasing evidence that germline mutations in CHEK2 do not cause Li-
Fraumeni syndrome. Hum Mutat 2002, 20:460-462.
11. Bartek J, Falck J, Lukas J: Chk2 kinase: a busy messenger. Nat Rev Mol Cell
Biol 2001, 2:877-886.
12. Matsuoka S, Huang M, Elledge SJ: Linkage of ATM to cell cycle regulation
by the Chk2 protein kinase. Science 1998, 282:1893-1897.
13. Ahn JY, Li X, Davis HL, Canman CE: Phosphorylation of threonine 68
promotes oligomerization and autophosphorylation of the Chk2 protein
kinase via the Forkhead-associated domain. J Biol Chem 2002,
277:19389-19395.
14. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH: hCds1-mediated
phosphorylation of BRCA1 regulates the DNA damage response. Nature
2000, 404:201-204.
15. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J: The ATM-Chk2-Cdc25A
checkpoint pathway guards against radioresistant DNA synthesis. Nature
2001, 410:842-847.
16. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J: The DNA damage-
dependent intra-S phase checkpoint is regulated by parallel pathways.
Nat Genet 2002, 30:290-294.
17. Bartek J, Lukas J: Chk1 and Chk2 kinases in checkpoint control and
cancer. Cancer Cell 2003, 3:421-429.
18. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE,
Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP,
Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li-
Fraumeni syndrome. Science 1999, 286:2528-2531.
19. Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O,
Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C,
Bartek J, Kallioniemi OP, Nevanlinna H: A CHEK2 genetic variant
contributing to a substantial fraction of familial breast cancer. Am J Hum
Genet 2002, 71:432-438.
20. Kilpivaara O, Vahteristo P, Falck J, Syrjäkoski K, Eerola H, Easton D,
Bartkova J, Lukas J, Heikkilä P, Aittomäki K, Holli K, Blomqvist C,
Kallioniemi OP, Bartek J, Nevanlinna H: CHEK2 variant I157T may be
associated with increased breast cancer risk. Int J Cancer 2004,
111:543-547.
21. Staalesen V, Falck J, Geisler S, Bartkova J, Børresen-Dale AL, Lukas J,
Lillehaug JR, Bartek J, Lønning PE: Alternative splicing and mutation status
of CHEK2 in stage III breast cancer. Oncogene 2004, 23:8535-8544.
22. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM,
Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC,
Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D,
Haber DA, Freedman ML: Genetic and functional analysis of CHEK2
(CHK2) variants in multiethnic cohorts. Int J Cancer 2007, 121:2661-2667.
23. Le Calvez-Kelm F, Lesueur F, Damiola F, Vallée M, Voegele C, Babikyan D,
Durand G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T,
Thomas A, Byrnes GB, Breast Cancer Family Registry, Hopper JL,
Southey MC, Andrulis IL, John EM, Tavtigian SV: Rare, evolutionarily
unlikely missense substitutions in CHEK2 contribute to breast cancer
susceptibility: results from a breast cancer family registry case-control
mutation-screening study. Breast Cancer Res 2011, 13:R6.
Desrichard et al. Breast Cancer Research 2011, 13:R119
http://breast-cancer-research.com/content/13/6/R119
Page 9 of 1124. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A,
Pietschmann A, Nestle-Krämling C, Rhiem K, Hüttner C, von Lindern C,
Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D,
Schmutzler RK, Arnold N: Limited relevance of the CHEK2 gene in
hereditary breast cancer. Int J Cancer 2004, 110:320-325.
25. Kleibl Z, Novotny J, Bezdickova D, Malik R, Kleiblova P, Foretova L,
Petruzelka L, Ilencikova D, Cinek P, Pohlreich P: The CHEK2 c.1100delC
germline mutation rarely contributes to breast cancer development in
the Czech Republic. Breast Cancer Res Treat 2005, 90:165-167.
26. Schwarz JK, Lovly CM, Piwnica-Worms H: Regulation of the Chk2 protein
kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol
Cancer Res 2003, 1:598-609.
27. Sodha N, Mantoni TS, Tavtigian SV, Eeles R, Garrett MD: Rare germ line
CHEK2 variants identified in breast cancer families encode proteins that
show impaired activation. Cancer Res 2006, 66:8966-8970.
28. Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ:
Risk factors for early age at breast cancer onset: the “COSA program”
population-based study. Anticancer Res 2007, 27:1087-1094.
29. National Center for Biotechnology Information Entrez Gene database:[http://
www.ncbi.nlm.nih.gov/gene].
30. Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA: A robust
method for detecting CHK2/RAD53 mutations in genomic DNA. Hum
Mutat 2002, 19:173-177.
31. Sunyaev S, Ramensky V, Bork P: Towards a structural basis of human non-
synonymous single nucleotide polymorphisms. Trends Genet 2000,
16:198-200.
32. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de
Silva D, Zharkikh A, Thomas A: Comprehensive statistical study of 452
BRCA1 missense substitutions with classification of eight recurrent
substitutions as neutral. J Med Genet 2006, 43:295-305.
33. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV:
Computational approaches for predicting the biological effect of p53
missense mutations: a comparison of three sequence analysis based
methods. Nucleic Acids Res 2006, 34:1317-1325.
34. Ng PC, Henikoff S: SIFT: predicting amino acid changes that affect
protein function. Nucleic Acids Res 2003, 31:3812-3814.
35. Ensembl Comparative Genomics database:[http://useast.ensembl.org/info/
docs/compara/index.html].
36. UniProt Consortium: UniProtKB/Swiss-Prot database:[http://www.uniprot.org/
uniprot/].
37. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7:248-249.
38. Pertea M, Lin X, Salzberg SL: GeneSplicer: a new computational method
for splice site prediction. Nucleic Acids Res 2001, 29:1185-1190.
39. Yeo G, Burge CB: Maximum entropy modeling of short sequence motifs
with applications to RNA splicing signals. J Comput Biol 2004, 11:377-394.
40. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M,
Béroud C: Human Splicing Finder: an online bioinformatics tool to
predict splicing signals. Nucleic Acids Res 2009, 37:e67.
41. Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K,
Takeuchi S, Koeffler HP: Mutations of the CHK2 gene are found in some
osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes
Chromosomes Cancer 2002, 33:17-21.
42. Shults MD, Janes KA, Lauffenburger DA, Imperiali B: A multiplexed
homogeneous fluorescence-based assay for protein kinase activity in
cell lysates. Nat Methods 2005, 2:277-283.
43. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI,
Dammann O, Bremer M, Karstens JH, Sohn C, Dörk T: Association of two
mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005,
116:263-266.
44. Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T,
Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M,
Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J,
Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubiński J: CHEK2 is a
multiorgan cancer susceptibility gene. Am J Hum Genet 2004,
75:1131-1135.
45. Osorio A, Rodríguez-López R, Díez O, de la Hoya M, Ignacio Martínez J,
Vega A, Esteban-Cardeñosa E, Alonso C, Caldés T, Benítez J: The breast
cancer low-penetrance allele 1100delC in the CHEK2 gene is not present
in Spanish familial breast cancer population. Int J Cancer 2004, 108:54-56.
46. Lee AS, Ang P: CHEK2*1100delC screening of Asian women with a family
history of breast cancer is unwarranted. J Clin Oncol 2008, 26:2419-2420.
47. Zhang S, Phelan CM, Zhang P, Rousseau F, Ghadirian P, Robidoux A,
Foulkes W, Hamel N, McCready D, Trudeau M, Lynch H, Horsman D, De
Matsuda ML, Aziz Z, Gomes M, Costa MM, Liede A, Poll A, Sun P, Narod SA:
Frequency of the CHEK2 1100delC mutation among women with breast
cancer: an international study. Cancer Res 2008, 68:2154-2157.
48. Narod SA: Testing for CHEK2 in the cancer genetics clinic: ready for
prime time? Clin Genet 2010, 78:1-7.
49. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK,
Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML,
Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W: Mutations in
CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003,
72:270-280.
50. Baeyens A, Claes K, Willems P, De Ruyck K, Thierens H, Vral A:
Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
Cancer Genet Cytogenet 2005, 163:106-112.
51. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J,
Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P,
Tollenaar RA, Klijn JG: Tumour characteristics and prognosis of breast
cancer patients carrying the germline CHEK2*1100delC variant. J Med
Genet 2004, 41:731-735.
52. Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH,
Greene MH, Struewing JP: CHEK2:1100delC and female breast cancer in
the United States. Int J Cancer 2004, 112:541-543.
53. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P,
Johnson S, Yossepowitch O, Huang H, Satagopan J, Robson M, Scheuer L,
Nafa K, Ellis N: Frequency of CHEK2*1100delC in New York breast cancer
cases and controls. BMC Med Genet 2003, 4:1.
54. Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C,
Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U,
GENICA Network: German populations with infrequent CHEK2*1100delC
and minor associations with early-onset and familial breast cancer. Eur J
Cancer 2005, 41:2896-2903.
55. CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and
susceptibility to breast cancer: a collaborative analysis involving 10,860
breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet
2004, 74:1175-1182.
56. Weischer M, Bojesen SE, Tybjærg-Hansen A, Axelsson CK, Nordestgaard BG:
Increased risk of breast cancer associated with CHEK2*1100delC. J Clin
Oncol 2007, 25:57-63.
57. Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG: The CHEK2
1100delC mutation is not present in Korean patients with breast cancer
cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat 2008,
112:569-573.
58. McInerney NM, Miller N, Rowan A, Colleran G, Barclay E, Curran C, Kerin MJ,
Tomlinson IP, Sawyer E: Evaluation of variants in the CHEK2, BRIP1 and
PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat
2010, 121:203-210.
59. Scharrer U, Skrzypczak-Zielinska M, Wituszynska W, Mierzejewski M, Krause K,
Cybulski C, Froster UG: A simple method of investigating mutations in
CHEK2 by DHPLC: a study of the German populations of Saxony,
Saxony-Anhalt, and Thuringia. Cancer Genet Cytogenet 2010, 199:48-52.
60. Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R,
Olson ER, Wolitzer AL, Seminara D, Whittemore AS, Concannon P: The
CHEK2*1100delC allelic variant and risk of breast cancer: screening
results from the Breast Cancer Family Registry. Cancer Epidemiol
Biomarkers Prev 2006, 15:348-352.
61. De Jong MM, Van der Graaf WTA, Nolte IM, Te Meerman GJ, Oosterwijk JC,
Van der Steege G, Boezen M, Schaapveld M, Kleibeuker JH, De Vries EGE:
Increased CHEK2 1100delC genotype frequency (also) in unselected
breast cancer patients [abstract 9536]. J Clin Oncol 2004, 22(14
Supplement):844s.
62. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A,
Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C,
Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P,
Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M: The CHEK2
1100delC mutation identifies families with a hereditary breast and
colorectal cancer phenotype. Am J Hum Genet 2003, 72:1308-1314.
63. Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD,
Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA: CHEK2 variants in
Desrichard et al. Breast Cancer Research 2011, 13:R119
http://breast-cancer-research.com/content/13/6/R119
Page 10 of 11susceptibility to breast cancer and evidence of retention of the wild
type allele in tumours. Br J Cancer 2002, 87:1445-1448.
64. Margolin S, Eiberg H, Lindblom A, Bisgaard ML: CHEK2 1100delC is
prevalent in Swedish early onset familial breast cancer. BMC Cancer 2007,
7:163.
65. Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA: Frequency
of CHEK2 mutations in a population based, case-control study of breast
cancer in young women. Breast Cancer Res 2004, 6:R629-R635.
66. Fletcher O, Johnson N, dos Santos Silva I, Kilpivaara O, Aittomäki K,
Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A,
Schmidt MK, Van’t Veer LJ, Bremer M, Dörk T, Chekmariova EV,
Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H,
Justenhoven C, Ashworth A, Peto J: Family history, genetic testing, and
clinical risk prediction: pooled analysis of CHEK2*1100delC in 1,828
bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers
Prev 2009, 18:230-234.
67. Mellemkjaer L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J,
Børresen-Dale AL, Stovall M, Langholz B, Bernstein L, Lynch CF, Malone KE,
Haile RW, Andersson M, Thomas DC, Concannon P, Capanu M, Boice JD Jr,
WECARE Study Collaborative Group, Bernstein JL: Risk for contralateral
breast cancer among carriers of the CHEK2*1100delC mutation in the
WECARE Study. Br J Cancer 2008, 98:728-733.
68. Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T,
Wokolorczyk D, Jakubowska A, Kowalska E, Oszurek O, Narod SA, Lubinski J:
CHEK2-positive breast cancers in young Polish women. Clin Cancer Res
2006, 12:4832-4835.
69. Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A,
Górski B, Wokołorczyk D, Masojć B, Narod SA, Lubiński J: Estrogen receptor
status in CHEK2-positive breast cancers: implications for
chemoprevention. Clin Genet 2009, 75:72-78.
70. Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Debniak T,
Wokołorczyk D, Jakubowska A, Serrano-Fernández P, Dörk T, Narod SA,
Lubiński J: Effect of CHEK2 missense variant I157T on the risk of breast
cancer in carriers of other CHEK2 or BRCA1 mutations. J Med Genet 2009,
46:132-135.
71. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG,
Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA,
Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N, Breast Cancer
Linkage Consortium: Variants in CHEK2 other than 1100delC do not make
a major contribution to breast cancer susceptibility. Am J Hum Genet
2003, 72:1023-1028.
doi:10.1186/bcr3062
Cite this article as: Desrichard et al.: CHEK2 contribution to hereditary
breast cancer in non-BRCA families. Breast Cancer Research 2011 13:R119.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Desrichard et al. Breast Cancer Research 2011, 13:R119
http://breast-cancer-research.com/content/13/6/R119
Page 11 of 11